AbbVie director Jennifer L. Davis to resign board seat effective November 2, 2026
Davis is stepping down after being named CEO of Align Technology, with AbbVie stating the move is unrelated to any internal dispute.
AbbVie Inc. disclosed in an 8-K filing dated October 28, 2026 that Class II director Jennifer L. Davis notified the company's board of her intent to resign, with the resignation effective November 2, 2026, following her appointment as chief executive officer of Align Technology, Inc.1
The filing specifies that her departure from the board is not tied to any disagreement with AbbVie regarding the company's operations, policies, or practices.1
The report was signed on November 2, 2026 by Perry C. Siatis, AbbVie's Executive Vice President, General Counsel and Secretary. No further details on board succession or replacement plans were included in the filing.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.